



# AJOONI BIOTECH LIMITED

Regd. Office: D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.)

Corp Office: H.No 1769, Phase 3B2, Mohali-160059

Phone: 0172-5020758-69 Website: [www.ajoonibiotech.com](http://www.ajoonibiotech.com)

E-mail: [ajooni.biotech@gmail.com](mailto:ajooni.biotech@gmail.com) / [info@ajoonibiotech.com](mailto:info@ajoonibiotech.com)

CIN: L85190PB2010PLC040162

November 13, 2025

To,  
National Stock Exchange of India Ltd  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400051

Dear Sir / Madam,

**SUB: Outcome of the Board Meeting held on Thursday, November 13, 2025, pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015.**

**SYMBOL: AJOONI**

Dear Sir,

With reference to the above captioned subject, we wish to inform you that the Board of Directors of the Company held their meeting on Thursday, 13<sup>th</sup> November 2025 at 10.30 a.m. and concluded at 11.00 a.m. at the Corporate Office of the company situated at House No. 1769, Phase 3B2, Mohali, Punjab. Following transactions were considered and approved:

1. Un-audited Financial Results for the quarter and half year ended September 30, 2025.
2. Limited Review Report from the auditor for the quarter and half year ended September 30, 2025.
3. Any other matter with the permission of the Chair.

Kindly take same on your records.

**Thanking You,  
Yours Truly,  
For Ajooni Biotech Limited**

**Swati Vijan  
Company Secretary  
FCS13627**



# AJOONI BIOTECH LIMITED

Regd. Office: D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.)

Corp Office: H.No 1769, Phase 3B2, Mohali-160059

Phone: 0172-5020758-69 Website: [www.ajoonibiotech.com](http://www.ajoonibiotech.com)

E-mail: [ajooni.biotech@gmail.com](mailto:ajooni.biotech@gmail.com) / [info@ajoonibiotech.com](mailto:info@ajoonibiotech.com)

CIN: L85190PB2010PLC040162

November 13, 2025

To,  
National Stock Exchange of India Ltd  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400051

Dear Sir / Madam,

**SYMBOL: AJOONI**

**Sub.: Approval of Un-Audited Financial Results for the quarter and half year ended 30<sup>th</sup> September 2025.**

Dear Sir,

Pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015, we wish to inform that the Board of Directors of the Company at their meeting held on Thursday, November 13, 2025 at the Corporate Office of the company have considered and approved the un-Audited Financial Statements for the quarter and half year ended on 30<sup>th</sup> September 2025. In these regards, we are enclosing herewith:

1. Un-Audited Financial Results for the quarter and half year ended on 30<sup>th</sup> September 2025 as recommended by the Audit Committee.
2. Limited Review Report from the auditor for the quarter and half year ended on 30<sup>th</sup> September 2025.

You are requested to kindly take the same on record.


Thanking You,  
Yours Truly,  
For Ajooni Biotech Limited

Swati Vijan  
Company Secretary  
FCS13627

**AJOONI BIOTECH LIMITED**  
**CIN : L85190PB2010PLC040162**

**STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER 2025(In Lakhs)**

	PARTICULARS	QUARTER ENDED					Year Ended (Audited)
		30.09.2025	30.06.2025	30.09.2024	Period Ended (UnAudited)	Period Ended (UnAudited)	31.03.2025
					30.09.2025	30.09.2024	
<b>I</b>	<b>Income</b>						
	Revenue from operations	3,173.51	3,126.77	2,572.44	6,300.28	5,138.29	11,469.19
	Other income	14.75	64.54	30.96	79.29	34.63	206.90
	<b>Total income from operations</b>	<b>3,188.26</b>	<b>3,191.31</b>	<b>2,603.40</b>	<b>6,379.57</b>	<b>5,172.92</b>	<b>11,676.09</b>
<b>II</b>	<b>Expenses</b>						
	Cost of Material Consumed	2,493.10	2,564.17	2,247.25	5,057.27	4,495.90	9,715.42
	Change In Inventories	6.78	(4.18)	9.41	2.60	7.77	(12.65)
	Employee benefit expenses	111.00	99.21	70.31	210.21	127.59	275.73
	Finance costs	17.21	8.46	5.90	25.67	20.92	33.43
	Depreciation and amortization expenses	24.54	24.83	22.56	49.37	44.88	109.35
	Payment to NSE						
	Other expenses	412.26	396.10	168.50	808.36	333.79	1,121.88
	<b>Total expenses</b>	<b>3,064.89</b>	<b>3,088.59</b>	<b>2,523.93</b>	<b>6,153.48</b>	<b>5,030.85</b>	<b>11,243.16</b>
<b>III</b>	<b>Profit/(Loss) before exceptional items and tax</b>	<b>123.37</b>	<b>102.72</b>	<b>79.47</b>	<b>226.09</b>	<b>142.07</b>	<b>432.93</b>
<b>IV</b>	<b>Exceptional items</b>						
<b>V</b>	<b>Profit/(Loss) before tax</b>	<b>123.37</b>	<b>102.72</b>	<b>79.47</b>	<b>226.09</b>	<b>142.07</b>	<b>432.93</b>
<b>VI</b>	<b>Tax expenses</b>						
	a) Current tax	32.08	22.50	19.07	54.58	34.27	102.42
	b) Deferred tax	1.92	(2.08)	(1.11)	(0.16)	(0.53)	6.70
	b) Mat Credit						
<b>VII</b>	<b>Net Profit/(Loss) for the period/year</b>	<b>93.21</b>	<b>78.14</b>	<b>61.51</b>	<b>171.35</b>	<b>108.33</b>	<b>337.21</b>
<b>VIII</b>	<b>Other comprehensive income (net of tax)</b>						
	loss:			54.14	-	54.14	(26.10)
	<b>Total other comprehensive income</b>						<b>(26.10)</b>
<b>IX</b>	<b>Total comprehensive income for the period/year (VII+VIII)</b>	<b>93.21</b>	<b>78.14</b>	<b>115.65</b>	<b>171.35</b>	<b>162.47</b>	<b>311.10</b>
<b>X</b>	<b>Paid-up equity share capital (face value of the share shall be indicated)</b>	<b>3,444.87</b>	<b>3,444.87</b>	<b>3,444.87</b>	<b>3,444.87</b>	<b>3,444.87</b>	<b>3,444.87</b>
<b>XI</b>	<b>Other equity (excluding revaluation reserve)</b>	<b>5,456.23</b>	<b>5,441.16</b>	<b>5,214.39</b>	<b>5,534.37</b>	<b>5,214.39</b>	<b>5,363.02</b>



XII	EPS in Rs. (Face Value of Rs.2/- each)*				-		
	-Basic	0.08	0.02	0.03	0.10	0.03	0.20
	-Diluted	0.08	0.02	0.03	0.10	0.03	0.20

Notes:

1. The above results are as per Regulation 33 of the SEBI (LODR) Regulations, 2015 as amended and have been taken on record by Board of Directors at its meeting held on 10.11.2025 after being reviewed by the Audit Committee.
2. The company is having single segment in accordance with IND AS 108 "operating segments". and therefore segment reporting is not applicable to the Company.
3. Due to re-grouping of schedules, and as per applicability of IND-AS, there has been a difference in the figures as reported earlier.

For Ajooni Biotech Limited


Jasjit Singh  
Managing Director  
DIN: 01937631


Place : Mohali

Date : 13/11/2025



PARTICULARS	30TH September 2025	31ST MARCH 2025
<b><u>I. ASSETS</u></b>		
<b><u>(1) Non - Current Assets</u></b>		
a) Property, Plant and Equipment	1,098.54	1,093.31
b) Capital Work In Progress	1,146.52	29.29
c) Investment Property		-
d) Goodwill		-
e) Other Intangible Assets	41.94	47.93
f) Intangible Assets Under Development		-
g) Biological Assets other than Bearer Plants		-
h) Financial Assets		
(1) Investments	336.00	349.36
(2) Trade Receivables		-
(3) Loans		-
(4) Other Financial Assets	0.00	1,506.79
i) Deffered Tax Asset (net)	36.00	37.92
j) Other Non Current Asset	275.11	240.11
<b><u>(2) Current Assets</u></b>		
a) Inventories	2,325.64	2,398.69
b) Financial Assets		
(1) Investments		
(2) Trade Receivables	1,581.72	1,621.64
(3) Cash & Cash Equivalent	1,528.70	683.02
(4) Bank Balances other than (iii) above		
(5) Loans	1,993.95	1,330.65
(6) Other Financial Asset		27.37
c) Current Tax Assets (net)		-
d) Other Current Asset	46.96	139.03
<b>TOTAL</b>	<b>10,411.08</b>	<b>9,505.11</b>
<b><u>II EQUITY AND LIABILITIES</u></b>		



<b>(1) Equity</b>		
a) Equity Share Capital	3,444.87	3,444.87
b) Other Equity	5,534.37	5,363.02
<b>(2) Non-Current Liabilities</b>		
a) Financial Liabilities		
(1) Borrowings	887.09	193.97
(2) Trade Payables		
(3) Other Financial Liabilities		
b) Employee Benefit Obligations	22.06	21.13
c) Deferred Tax Liability (net)		-
d) Other Non Current Liability		-
<b>(3) Current Liabilities</b>		
a) Financial Liabilities		
(1) Borrowings	0.00	0.00
(2) Trade Payables	445.44	349.52
(3) Other Financial Liabilities		
b) Employee Benefit Obligations	0.00	0.93
c) Other Current Liabilities	45.17	29.25
d) Current tax liabilities (Net)	32.08	102.42
<b>TOTAL</b>	<b>10,411.08</b>	<b>9,505.11</b>
<div style="display: flex; justify-content: space-between; align-items: flex-start; padding-top: 20px;"> <div> <p><b>Place : Mohali</b></p> <p><b>Date : 13.11.2025</b></p> </div> <div style="text-align: right;"> <p>For Ajooni Biotech Limited</p>  <p>Jasjot Singh</p> <p>Managing Director</p> <p>DIN: 01937631</p> </div> </div>		

CASH FLOW STATEMENT			30TH SEPTEMBER 2025
"A" (1)	<b>CASH FLOW FROM OPERATING ACTIVITIES</b>		
	Profit/(Loss) Before Tax		226.09
	Adjustments for:		
	Depreciation & Amortization	49.37	
	Interest & Finance Charges	25.67	
	Interest Income	-28.00	47.04
	<b>Operating Profit before Working Capital Changes</b>		273.13
	Adjustments for:		
	Decrease/(Increase) in Receivables	39.92	
	Decrease/(Increase) in Inventories	73.05	
	Decrease/(Increase) in Loans and Other Advances	835.86	
	Decrease/(Increase) in Other Current Assets	92.07	
	Increase/(Decrease) in Trade Payables	95.92	
	Increase/(Decrease) in Other Current Liabilities	-55.35	1,081.47
	<b>Cash generated from operations</b>		1,354.60
	Tax paid prev year		
	<b>Net Cash flow from Operating activities</b>		1,354.60
	<b>(2) CASH FLOW FROM INVESTING ACTIVITIES</b>		
	Purchase of Tangible Assets/ Intangible Assets/ Capital Work-In-Progress	-1171.54	
	(Increase)/Decrease by sale/purchase in Non-Current Investment	-84.17	
	Interest Income	28.00	
	<b>Net Cash used in Investing activities</b>		-1227.71
	<b>(3) CASH FLOW FROM FINANCING ACTIVITIES</b>		
	Proceeds from/ (Repayment) of Long term Borrowings	693.12	
	Proceeds from issue of share capital premium received	0.00	
	Increase/(Decrease) in Short Term Borrowings	0.00	
	Interest and Other Finance Costs paid	25.67	
	<b>Net Cash used in financing activities</b>		718.79



"B"	Net increase in cash & Cash Equivalents			845.68
	Add: Cash and Cash equivalents at the Beginning of the Year 1.04.2025			683.02
"c"	Cash & Cash Equivalents at 30.09.2025			1,528.70







**NARINDER KUMAR AND COMPANY**  
**CHARTERED ACCOUNTANTS**

SCO 65-B (1st Floor) City Heart,  
Kharar Chandigarh Road,  
Kharar, SAS Nagar Mohali-140301  
Mobile : 98154 50065  
Email : nkgargca@yahoo.co.in

## Limited Review Report

Ref. No. ....

Dated .....

Review Report to Board of Directors of M/s Ajooni Biotech Limited.

We have reviewed the accompanying statement of unaudited financial results of M/s Ajooni Biotech Limited having Regd. office at D-118, Industrial Area, Phase-VII, Mohali Punjab-160055. for the period ended 30th September, 2025.(the Statement) attached herewith , being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and disclosure requirements) regulations 2015 (as amended) , Including relevant circulars issued by the Securities and Exchange Board of India (SEBI) from time to Time.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For NARINDER KUMAR AND COMPANY  
Chartered Accountants

*Narinder*  
(NARINDER KUMAR GARG)  
PARTNER  
M.NO-080287



Date:-13.11.2025

UDIN:- 25080287BMLIZW1234